GlassScriptPhysician profile
Darline Durand
NPI 1912185455
$1,016.95
in general payments reported to CMS, 2019-2025
24 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $78.54 · 2022: $105 · 2023: $20.28 · 2024: $256 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.99 | 2024 | Jaypirca |
| Merck Sharp & Dohme LLC | $116.66 | 2024-2025 | Keytruda, Keytruda Qlex, Welireg |
| Astrazeneca Pharmaceuticals LP | $105.72 | 2025 | Calquence |
| Stemline Therapeutics INC. | $71.95 | 2025 | Orserdu |
| Novartis Pharmaceuticals Corporation | $67.90 | 2021-2022 | |
| Puma Biotechnology, INC. | $51.78 | 2024-2025 | |
| Pharmaessentia USA Corporation | $51.45 | 2025 | Besremi |
| Janssen Biotech, INC. | $49.24 | 2025 | Rybrevant, Erleada |
| Abbott Laboratories | $45.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.24 | 2025 | Fruzaqla |
| Karyopharm Therapeutics INC. | $32.27 | 2024 | Xpovio |
| Coherus Oncology, INC. | $29.04 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.76 | 2025 | |
| Genentech USA, INC. | $24.00 | 2025 | Itovebi |
| Taiho Oncology, INC. | $22.10 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.28 | 2025 | Lifevest |
| Kci USA, INC. | $20.86 | 2022 | |
| Biogen, INC. | $20.28 | 2023 | Vumerity |
| Pharmacosmos Therapeutics INC. | $20.16 | 2024 | Cosela |
| Lantheus Medical Imaging, INC. | $16.90 | 2021 | |
| Amgen INC. | $16.79 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $16.12 | 2022 | |
| Genmab U.S., INC. | $16.06 | 2024 | Tivdak |
| Nuvation Bio INC. | $15.04 | 2025 | Ibtrozi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darline Durand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.